Illumina, Inc. (ILMN)

Illumina's stock has experienced significant movement in the past six months, including an 80% surge, trading between $68.70 and $155.53. Illumina reported Q4 CY2025 revenue of $1.16 billion, surpassing expectations by 3.2% with a 5% year-on-year increase. The company provided full-year 2026 revenue guidance of $4.5 billion to $4.6 billion, with projected 2-4% organic growth excluding China. The recent acquisition of SomaLogic is expected to bolster Illumina's multiomics capabilities, though it is anticipated to dilute EPS by $0.18. As of March 21, 2026, the consensus recommendation from eighteen research firms was "Hold," with an average twelve-month target price of $129.6875. In February 2026, SVP Patricia Leckman sold 2,370 shares of the company's stock.

Illumina experiences a seasonal increase in ordering activity and backlog build for consumables, particularly noted in Q1, which signals positive underlying sequencing activity for the remainder of the year.

Illumina, Inc. is an American biotechnology company specializing in DNA sequencing and array-based technologies. The company develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function, serving customers in research, clinical, and applied markets. Illumina's major products and services include instruments like sequencing platforms and microarray scanners, kits and reagents, selection tools, software and analysis solutions like the BaseSpace Informatics Suite and DRAGEN Bio-IT Platform, and services such as sequencing and microarray services. Illumina's technologies are utilized in diverse applications including life sciences, oncology, reproductive health, agriculture, genetic and infectious diseases, and drug discovery and development.

Illumina's worldwide headquarters are located in San Diego, California, USA. The company maintains a global presence, serving over 155 countries with direct sales operations across North America, Europe, Latin America, and the Asia-Pacific region, complemented by distributors in other markets. Illumina also has office locations in Madison, WI; Foster City, CA; Baltimore, MD; and internationally in countries like Korea, Japan, Australia, New Zealand, and the United Kingdom.

Illumina's brand reputation in the past year has been influenced by regulatory and geopolitical challenges, including being placed on China's "Unreliable Entities List" and export restrictions. Illumina was ordered to pay $333 million to a U.S. unit of BGI for infringing two patents related to DNA-sequencing systems, and a jury also invalidated three patents owned by Illumina. Illumina has expanded its collaboration with Labcorp to advance precision oncology through sequencing solutions. The company has also highlighted customer breakthroughs in oncology using its spatial transcriptomics, epigenomics, and proteomics technologies. Illumina unveiled an 18-month roadmap of NovaSeq X updates, promising higher accuracy, throughput, speed, and flexibility, and announced a strategic consortium with Veritas Genetics to integrate whole-genome sequencing into preventive care.

Illumina's shareholder base is predominantly institutional, holding approximately 92.13% of the shares with 991 institutional owners and shareholders. Major institutional owners include Capital World Investors, The Vanguard Group, Inc., and BlackRock, Inc. Individual ownership accounts for about 2.84% of shares. Keith A. Meister is a significant individual shareholder, owning 7.66 million shares, representing 5.01% of the company. Recent insider trades include sales by several officers and a purchase by a director.